CLBIO Stock Overview
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Corline Biomedical AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr11.70 |
52 Week High | kr18.15 |
52 Week Low | kr9.64 |
Beta | 0.50 |
1 Month Change | 10.90% |
3 Month Change | -7.51% |
1 Year Change | -21.74% |
3 Year Change | 5.41% |
5 Year Change | -34.27% |
Change since IPO | 14.15% |
Recent News & Updates
Recent updates
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Shareholder Returns
CLBIO | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 10.9% | 8.4% | -1.3% |
1Y | -21.7% | 75.7% | 13.7% |
Return vs Industry: CLBIO underperformed the Swedish Pharmaceuticals industry which returned 75.7% over the past year.
Return vs Market: CLBIO underperformed the Swedish Market which returned 13.7% over the past year.
Price Volatility
CLBIO volatility | |
---|---|
CLBIO Average Weekly Movement | 5.8% |
Pharmaceuticals Industry Average Movement | 8.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.8% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CLBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: CLBIO's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 13 | Henrik Nittmar | www.corline.se |
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.
Corline Biomedical AB Fundamentals Summary
CLBIO fundamental statistics | |
---|---|
Market cap | kr251.44m |
Earnings (TTM) | -kr4.50m |
Revenue (TTM) | kr30.96m |
8.1x
P/S Ratio-55.9x
P/E RatioIs CLBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLBIO income statement (TTM) | |
---|---|
Revenue | kr30.96m |
Cost of Revenue | kr6.10m |
Gross Profit | kr24.85m |
Other Expenses | kr29.35m |
Earnings | -kr4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -0.21 |
Gross Margin | 80.29% |
Net Profit Margin | -14.53% |
Debt/Equity Ratio | 0% |
How did CLBIO perform over the long term?
See historical performance and comparison